Clinical trials: Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Stem Cell Transplant Complications
KIR Sequencing and Typing for Allograft in Nancy
The use of haploidentical donors for aHSCT has greatly increased this past decade leading to a major paradigm shift: while finding 10/10 HLA-matched donors represented the prior difficulty for decades, the current problem is…
- Trial name
- KIR-STAN (NCT04882605)
- Testing
- MHC typing, KIR typing, Assessment of KIR-based prediction scores
- Volunteers
- 156 people
- Sponsor
- Central Hospital, Nancy, France
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration
The purpose of this study is to evaluate the safety and the efficacy of Glycopyrrolate as pMDI after single and repeated administration.
- Trial name
- GLY2 (NCT01176903)
- Testing
- Glycopyrrolate, Tiotropium
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD, Respiratory Acidosis
Evaluation of the Effects on Carbon Dioxide (paCO2) of a New Oronasal Mask in Patients With Severe COPD Exacerbation Requiring Non-Invasive Mechanical Ventilation
This single-center, crossover study aims to investigate the effects of the new OptiNIV oronasal mask used during NIV in COPD patients with respiratory acidosis following an exacerbation.
- Trial name
- OPTIMUS-MASK (NCT07081776)
- Testing
- OptiNIV, Visairo
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
COPD (Chronic Obstructive Pulmonary Disease)
A Phase 2 Trial of JKN24011 in COPD
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07440524
- Testing
- JKN24011
- Where
- China
- Volunteers
- 215 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
COPD
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to…
- Trial name
- NCT02268396
- Testing
- Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
- Where
- 10 sites in United States
- Volunteers
- 138 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Chronic Obstructive Pulmonary Disease Severe, Muscle Weakness
Additional Manual Therapy Over Inspiratory Muscle Training in COPD
The benefits of inspiratory muscle training(IMT) in patients with chronic obstructive pulmonary disease(COPD) were reported.But in severe COPD patients, benefit from IMT may be limited.There is need for further research in new…
- Trial name
- NCT04533516
- Testing
- Manual therapy technics, Inspiratory Muscle Training
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Istinye University
COPD
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT02536508
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 64 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease, End-of-Life Fear
End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)
The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life.
- Conditions
- Chronic Obstructive Pulmonary Disease, End-of-Life Fear, Fear About Death and Dying, Depression
- Trial name
- NCT00792974
- Testing
- A brief psycho-educational intervention
- Where
- 2 sites in Germany
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
Severe Chronic Obstructive Pulmonary Disease
Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State
Design studies of nebulization in COPD does not respond adequately to the clinically relevant question: the intervention of administering nebulized bronchodilators at home it is likely to make a profit, compared to the standard…
- Trial name
- Nebuadom (NCT02103374)
- Testing
- Atrovent + Bricanyl or Atrovent + Ventoline
- Where
- 13 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Tours
COPD, Disease Progression
Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring
The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations…
- Trial name
- PROMETE (NCT02499068)
- Testing
- Telehealth
- Where
- 5 sites in Spain
- Volunteers
- 237 people
- Sponsor
- Arturo Garcia
Chronic Obstructive Pulmonary Disease
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with…
- Trial name
- NCT06789289
- Testing
- TQC2938 injection
- Where
- 40 sites in China
- Volunteers
- 256 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease, Respiratory Failure
Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation.
The hypothesis that is being tested is that the supplementation of L-arginine plus Vitamin C to multidisciplinary pulmonary rehabilitation (PR) in patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT06439875
- Testing
- effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation
- Where
- 3 sites in Italy
- Volunteers
- 101 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Exacerbation
Muscle Oxygenation in Chronic Obstructive Pulmonary Disease
The aim of our study is to examine the Peripheral Muscle Oxygenations at rest and in motion on the 2nd day of hospitalized patients and before discharge in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease and to…
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Exacerbation, Muscle Oxygenation
- Trial name
- NCT05808621
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people
- Sponsor
- Bandırma Onyedi Eylül University
Pulmonary Disease, Chronic Obstructive
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in…
- Trial name
- NCT01964352
- Testing
- tiotropium, olodaterol
- Where
- 77 sites in United States, Belgium and 8 more
- Volunteers
- 813 people
- Sponsor
- Boehringer Ingelheim
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca